Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP903 in advanced malignancies with PIK3CA mutations
NCT06846099Phase 1Completed
- Sponsor
- Risen Pharma
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS105 in Cervical Cancer (CC), endometrial cancer (EC), breast cancer and 2 more, sponsored by Risen Pharma. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 2 years and 5 more. Started Dec 2022; status: completed.
02
Drugs
JS105
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)breast cancerovarian cancersolid tumor
Beyond the preview
Go deeper on NCT06846099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846099.